![Wills Hughes-Wilson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Wills Hughes-Wilson
Corporate Officer/Principal en MEREO BIOPHARMA GROUP PLC .
Fortuna: 1 056 $ al 31/05/2024
Perfil
Wills Hughes-Wilson is currently the Chief Patient Access & Commercial Planning at Mereo BioPharma Group Plc.
Previously, she held positions as the Executive Director at European Biopharmaceutical Enterprises, Vice President-Health & Market Access Policy at Genzyme Corp., and VP-Health & Market Access Policy EMEA at Genzyme Therapeutics Ltd.
From 2016 to 2018, she served as the Chief Patient Access Officer & Senior VP at Swedish Orphan Biovitrum AB.
Ms. Hughes-Wilson graduated from the University of Durham.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
22/05/2024 | 1 530 ( 0.00% ) | 1 056 $ | 31/05/2024 |
Cargos activos de Wills Hughes-Wilson
Empresas | Cargo | Inicio |
---|---|---|
MEREO BIOPHARMA GROUP PLC | Corporate Officer/Principal | 01/03/2018 |
Antiguos cargos conocidos de Wills Hughes-Wilson.
Empresas | Cargo | Fin |
---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Public Communications Contact | 01/01/2018 |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - |
European Biopharmaceutical Enterprises
![]() European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Director/Miembro de la Junta | - |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Formación de Wills Hughes-Wilson.
University of Durham | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
MEREO BIOPHARMA GROUP PLC | Health Technology |
Empresas privadas | 3 |
---|---|
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
European Biopharmaceutical Enterprises
![]() European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | Health Technology |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Wills Hughes-Wilson